Press Releases from VAXIMM AG (4 total)
VAXIMM reports positive topline data from first oral cancer vaccine trial
- Study meets endpoints and demonstrates safety and tolerability of VXM01 -
Basel (Switzerland), Mannheim (Germany), February 7th, 2013 – VAXIMM AG, a Swiss-German biotech company…
VAXIMM completes enrollment of first oral cancer vaccine trial
Basel (Switzerland), Mannheim (Germany), October 22nd, 2012 – VAXIMM AG, a Swiss-German biotech company focusing on oral cancer vaccines, announced today that it completed enrollment…
VAXIMM receives grant to expand pipeline of oral cancer vaccines
Basel (Switzerland), Mannheim (Germany), October 2nd, 2012 – VAXIMM AG, a Swiss-German biotech company focusing on cancer vaccines, today announced that its German subsidiary VAXIMM…
Jean-Paul Prieels joins VAXIMM’s Board of Directors
Basel (Switzerland), Mannheim (Germany), May 03, 2012 – VAXIMM AG, a Swiss-German biotech spin-off from Merck KGaA focusing on cancer vaccines, announced today the appointment…
Go To Page:
